Blog & News
More blog posts
The New ICH E6 (R3) Guidelines: Impact on Clinical Trials
In anticipation of the new ICH GCP E6(R3) guidelines, which are due to be implemented in August / September 2024, as Arithmos we would like to discuss the evolution of clinical trial designs and proportional risks.
Corso Pratico di Alta Formazione in “Laboratori di GxP (Good for Practice) – Requisiti per svolgere la funzione di QA e GCP Auditor”
Italian Language | In collaborazione con il progetto DARE della Fondazione DARE, il corso si configura come un
primo step di formazione teorica per il raggiungimento della qualifica prevista dalla Normativa vigente
per Auditors GCP.
Report | Pharmacovigilance 2.0: Leveraging Analytics and Automation
Read this report that summarises the insights from twenty pharmaceutical industry professionals working in IT and pharmacovigilance departments
eTMF Integration: Benefits and Impact on QMS
Improve efficiency, security, & data quality in clinical trials with eTMF integration. Learn how it impacts QMS & benefits of integrating with CTMS & EDC systems.
The Essence of GLP Test Item Characterisation: Ensuring Precision in Non-Clinical Studies
Together with our GLP Auditor Michelle Anderson, we delve into the significance of test item characterisation in GLP.
Arithmos expands UK presence with new office in Pickmere, Knutsford
Arithmos expands its UK presence with new office in Pickmere, Knutsford to accommodate its business growth.
Massimo Raineri joins Arithmos as Senior Consultant, Clinical Business Partner
Arithmos welcomes Massimo Raineri to the team. Find out more about Arithmos’ new Senior Consultant, Clinical Business Partner.
A Letter from our CEO
Paolo Morelli, Founder and CEO of Arithmos, would like to thank our customers, partners, and employees for working together in 2023 towards creating better lives for patients around the world.
Read some thoughts on the Arithmos year.
Whitepaper | Analysis of Future Trends and Technologies in Pharmacovigilance
In this Whitepaper, we analyse the current and future changes in the pharmacovigilance field, and how technology plays a critical role.
5 Benefits of Performing a Vulnerability Assessment
As the Life Sciences industry embraces technology, vulnerability assessments and penetration testing are essential tools for securing your critical assets.
On Demand Webinar (Italian language) | I sistemi integrati per la gestione delle attività nel mondo dell’industria biomedicale: il caso VEEVA
Quali sono i benefici dei sistemi integrati, cloud based, per il mondo Life Sciences? Scopri, in questo webinar, le esperienze dirette di alcune importanti realtà farmaceutiche.
A look at Real World Data (RWD) and Real World Evidence (RWE)
A look at RWD and RWE, describing differences and their significant support to medicines evaluation and regulatory decision-making in Life Science.
